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ABSTRACT 
We conducted a cross-sectional analysis of baseline data from a UK cohort study which 
enrolled participants at risk of latent tuberculosis infection (LTBI, defined as a positive result 
for either of the two interferon gamma release assays (IGRAs)). Binomial regression with a 
log link was used to estimate crude and adjusted prevalence ratios (PRs) and 95% 
confidence intervals (CIs) for the relationship between diabetes mellitus (DM) and LTBI. 
Adjusted for age, sex, ethnicity, body mass index and the presence of other 
immunocompromising conditions, DM was associated with a 15% higher prevalence of LTBI 
(adjusted PR=1.15, 95% CI 1.02-1.30, p=0.025).  
 
Key words: Tuberculosis; Clinical epidemiology 
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To the editor: 
Diabetes mellitus (DM) and tuberculosis (TB) are major global public health priorities (1, 2). 
Many studies have assessed the relationship between DM and active TB disease (3). Data 
on the effect of DM on the risk of latent TB infection (LTBI) are more limited. A recent 
systematic review identified one cohort study, with an adjusted risk ratio of 4.40 (95% CI 
0.50-38.55), and 12 cross-sectional studies which generated a pooled adjusted odds ratio of 
1.18 (95% CI 1.06-1.30) (4).  
 
The PREDICT (Prognostic Evaluation of Diagnostic IGRAs Consortium) study was a 
prospective, multi-site UK cohort study aiming to evaluate the predictive values of interferon 
gamma release assays (IGRAs) for the development of active TB among recent entrants to 
the UK from high-burden countries and contacts of active TB cases (“contacts”). PREDICT 
was approved by the Brent Research Ethics Committee (reference 10/H0717/14) and is 
registered on clinicaltrials.gov (NCT01162265). In this study, we use baseline data from 
PREDICT to investigate the association between DM and LTBI. 
 
Recruitment took place between January 2011 and July 2015. After giving informed consent, 
participants completed a questionnaire and provided blood samples for IGRAs. Participants 
with evidence of active TB were excluded. The main exposure of interest in this secondary 
analysis was a self-reported history of DM. Data were also collected on the method of DM 
control used. The outcome of interest was LTBI, defined as a positive result for either or both 
of the two commercially available IGRAs, Quantiferon-TB Gold In-Tube (QFT-GIT – Qiagen) 
and TSpot.TB (Oxford Immunotec, Abingdon, UK). Participants with no valid IGRA results 
were excluded from this analysis. Other covariates on which data were collected are 
described in the Supplement.  
 
Binomial regression with a log link was used to estimate crude and adjusted prevalence 
ratios (PRs and aPRs) and 95% CIs for the relationship between DM and LTBI (5). Age and 
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sex were treated as a priori confounders. A causal diagram of the relationships between 
potential confounders and outcomes using directed acyclic graphs, interpreted using 
dagitty.net (6) (Figure S1), was used to identify the minimum set of other covariates required 
for adjustment. P values were derived from likelihood ratio tests. We assessed potential 
interactions between DM and age (3) and DM and ethnicity (7), as observed for active TB (3, 
7). All analyses used a complete-case approach. We conducted sensitivity analyses: 1) 
adjusting for age as a continuous variable using fractional polynomials (8); 2) using Poisson 
regression with robust standard errors (9); 3) restricting analysis to contacts; 4) including 
only participants who had concordant results for the two IGRAs; 5) repeating the primary 
analysis additionally adjusting for country of birth. Further methodological details and the 
questionnaire are provided in the Supplement. 
 
9157 participants were included in the analysis (Table 1, Table S2S1, Figure S2). 756 
participants (8.3%) reported having diabetes, of whom 535 provided information about how 
they controlled the condition: 409 taking medication, 55 on insulin, 20 using both insulin and 
other medication(s) and 51 through monitoring and/or diet only. 
 
Prevalence of a positive IGRA was 31.5% and 27.3% amongst those with and without DM, 
respectively (Table 1: unadjusted PR=1.15, 95% CI 1.03-1.29, p=0.012). Characteristics 
associated with a positive IGRA on univariate analysis included increasing age, male sex, 
being born outside the UK, being a contact, having had a previous TB diagnosis or previous 
contact with a TB patient, and immunosuppression (Table 1). IGRA positivity varied by 
ethnicity, being highest in the Black African ethnic group and lowest amongst Black 
Caribbean participants. There was no evidence that having a positive IGRA was associated 
with previous BCG vaccination, HIV status, BMI, smoking, or social risk factors (Table 1). 
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Table 1: Characteristics of participants with and without LTBI, and unadjusted prevalence 
ratios for the association with LTBI 
  IGRA 
positive 
[n (%)] 
IGRA 
negative 
[n (%)] 
Prevalence ratio 
(95% CI) 
p 
Total  2534 (27.7) 6623 (72.3)   
      
Diabetes No 2296 (27.3) 6105 (72.7) Referent  
(n = 9157) Yes 238 (31.5) 518 (68.5) 1.15 (1.03-1.29) 0.012 
      
Sex Male 1406 (30.9) 3149 (69.1) Referent  
(n = 9107) Female 1116 (24.5) 3436 (75.5) 0.79 (0.74-0.85) <0.001 
      
Age group  16-25 510 (22.6) 1747 (77.4) Referent  
(years) 26-35 887 (28.2) 2258 (71.8) 1.25 (1.14-1.37)  
(n = 9152) 36-45 470 (33.1) 949 (66.9) 1.47 (1.32-1.63)  
 >45 666 (28.6) 1665 (71.4) 1.26 (1.14-1.40) <0.001 
      
Country of birth Non-UK 2279 (29.7) 5385 (70.3) Referent  
(n = 9131) UK 245 (16.7) 1222 (83.3) 0.56 (0.50-0.63) <0.001 
      
Ethnicity Indian 1043 (27.8) 2716 (72.3) Referent  
(n = 8934) White 233 (21.0) 879 (79.1) 0.76 (0.67-0.86)  
 Black African 403 (37.0) 687 (63.0) 1.33 (1.21-1.46)  
 Mixed 270 (30.9) 603 (69.1) 1.11 (1.00-1.25)  
 Pakistani 264 (30.1) 614 (69.9) 1.08 (0.97-1.21)  
 Bangladeshi 134 (19.3) 561 (80.7) 0.69 (0.59-0.82)  
 Black Caribbean 37 (16.8) 183 (83.2) 0.61 (0.45-0.82)  
 Black Other / 
Chinese / Other 
78 (25.4) 229 (74.6) 0.92 (0.75-1.12) <0.001 
      
Type of participant Contact 1384 (29.6) 3286 (70.4) Referent  
(n = 9157) New entrant 1150 (25.6) 3337 (74.4) 0.86 (0.81-0.92) <0.001 
      
Previous BCG 
vaccination 
No 394 (27.8) 1024 (72.2) Referent  
(n = 7759) Yes 1724 (27.2) 4617 (72.8) 0.98 (0.89-1.07) 0.65 
      
Previous TB 
diagnosis 
No 2321 (26.7) 6368 (73.3) Referent  
(n = 9012) Yes 180 (55.7) 143 (44.3) 2.09 (1.88-2.31) <0.001 
      
Previous contact with 
TB case 
No 2080 (27.1) 5599 (72.9) Referent  
(n = 8833) Yes 355 (30.8) 799 (69.2) 1.14 (1.03-1.25) 0.01 
      
HIV positive No 2366 (27·9) 6121 (72·1) Referent  
(n = 8539) Yes 14 (26·9) 38 (73·1) 0·97 (0·62-1·51) 0.88 
      
Other 
immunosuppressiona  
No 2483 (27.9) 6425 (72.1) Referent  
(n = 9150) Yes 49 (20.3) 193 (79.8) 0.73 (0.56-0.93) 0.007 
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Smoking No 2038 (27.6) 5352 (72.4) Referent  
(n = 9125) Yes 489 (28.2) 1246 (71.8) 1.02 (0.94-1.11) 0.61 
      
BMI (kg/m2) <18.5 113 (26.3) 317 (73.7) Referent  
(n = 8589) 18.5 – 25  1155 (27.3) 3069 (72.7) 1.04 (0.88-1.23)  
 ≥25 1122 (28.5) 2813 (71.5) 1.09 (0.92-1.28) 0.38 
      
Any social risk  No 2407 (27.6) 6328 (72.4) Referent  
factorb (n = 9157) Yes 127 (30.1) 295 (69.9) 1.09 (0.94-1.27) 0.26 
 
a Other immunosuppressive factors considered were: history of using anti-TNF-α or other 
immunosuppressive drugs, solid organ transplant, haematological malignancy, jejunoileal 
bypass, chronic renal failure or haemodialysis, gastrectomy. 
b Social risk factors considered were: current or past homelessness, imprisonment or 
problem drug use. 
 
Complete covariate data were available for 8336 participants (91.0% of the included 
participants; Table S2 compares these 8336 participants with the 821 with incomplete data). 
Adjusting for sex, age group, ethnicity, immunosuppression and BMI, the aPR for the 
association between DM and LTBI was 1.15 (95% CI 1.02-1.30, p=0.025, Table S2S3). 
There was no evidence of interaction between DM and age group (p=0.22) and weak 
evidence of interaction between DM and ethnicity (p=0.055, Table S3S4). Sensitivity 
analyses produced similar results, although the aPR increased to 1.29 (95% CI 1.09-1.52, 
p=0.002) when analysis was restricted to contacts (Table S4S5). 
 
Our results are likely to be generalisible to migrants and contacts in the UK (although there 
were some differences between participants included and excluded from the analysis 
[Tables S1 and S2]), but perhaps not to other settings with different distributions of risk 
factors including country of birth and ethnicity.  We used both of the commercially available 
IGRAs, and conducted a sensitivity analysis restricted to participants with concordant 
results, providing additional certainty regarding the diagnosis of LTBI. Limitations of the 
study include the self-reported nature of DM status, although this was frequently supported 
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by reported use of insulin or oral hypoglycaemic agents. Any participants with undiagnosed 
DM would be misclassified; this would be non-differential with respect to IGRA status and 
could bias our estimates towards the null. It is also possible that DM (and other forms of 
immunosuppression) influences the response to IGRA (10). 
  
This is a cross-sectional analysis so we cannot be certain whether DM onset preceded LTBI. 
However, the association persisted when analysis was restricted to contacts, who were 
considered likely to have acquired infection recently. Residual confounding (e.g. by 
socioeconomic status) could inflate our estimated aPRs. Reported HIV prevalence was low 
and may be an underestimate as it was based on self-report.  
 
Consistent with a previous systematic review and meta-analysis (4), this study suggests that, 
after adjustment for age, sex, BMI, ethnicity and immunosuppression, DM is associated with 
a small increase in the prevalence of positive IGRA results, amongst individuals at high risk 
of LTBI. Prospective studies are needed to further investigate the temporal relationship 
between DM and both infection and disease onset. 
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